Global Neuroendocrine Tumor Treatment Market Growth Rate 2024, Forecast To 2033
8 Mar, 2024
The neuroendocrine tumor treatment market has experienced rapid growth, expanding from $1.94 billion in 2023 to $2.16 billion in 2024, with a CAGR of 11.4%. This growth is attributed to advancements in clinical research and understanding. Projected to reach $3.19 billion by 2028, with a CAGR of 10.3%, this growth will be driven by precision medicine advancements and rising incidence rates.
Global Neuroendocrine Tumor Treatment Market Key Driver
The increasing prevalence of neuroendocrine tumors is expected to drive growth in the neuroendocrine tumor treatment market. These rare tumors affect thousands globally, necessitating effective treatment options. Reports from the American Society of Clinical Oncology and Cancer Australia highlight the significant burden of neuroendocrine tumors in the US and Australia. Consequently, the rising prevalence of these tumors underscores the demand for advanced treatment modalities.
Get A Free Sample Of The Global Neuroendocrine Tumor Treatment Market ReportGlobal Neuroendocrine Tumor Treatment Market Segments
The neuroendocrine tumor treatment market covered in this report is segmented –
1) Product:Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, Others Products
2) Indication:Lungs, Pancreas, Gastrointestinal, Others Indications
3) End-Users:Hospitals, Oncology Centers, Other End-Users
By Geography: The countries covered in the neuroendocrine tumor treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the neuroendocrine tumor treatment market in 2023. The regions covered in the neuroendocrine tumor treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Neuroendocrine Tumor Treatment Industry Players
Pfizer Inc.; F Hoffmann-La Roche AG; Abbvie Inc.; Novartis AG; Sanofi SA; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; AstraZeneca; GlaxoSmithKline PLC; Takeda Pharmaceutical; Eli Lilly And Company; Amgen Inc.; Merck & Co. Inc.; Boehringer Ingelheim International GmbH; Servier; Teva Pharmaceutical Industries Ltd.; Ipsen Pharma SAS; Exelixis Inc.; Advanced Accelerator Applications SA; Hutchison Medipharma Ltd.; Dauntless Pharmaceuticals Inc.; Tarveda Therapeutics; GlycoMira Therapeutics Inc; AVEO Pharmaceuticals Inc.; Progenics Pharmaceuticals Inc.; Callisto Pharmaceuticals Pvt Ltd.; Chiasma Inc.
Get The Full Global Neuroendocrine Tumor Treatment Market Report
Neuroendocrine Tumor Treatment Market Overview
Neuroendocrine tumor treatment refers to the process of medical interventions and therapies aimed at managing and controlling neuroendocrine tumors (NETs). Neuroendocrine tumors are a rare type of cancer arising from neuroendocrine cells that regulate hormone production throughout the body. Neuroendocrine tumor treatment involves various approaches to target and control tumor growth, relieve symptoms, and improve the patient's quality of life.